MAP2K7 and neoplasm: Indeed, sorafenib, the only approved molecular-targeted agent, which can suppress angiogenesis and tumor growth by inhibiting the Raf/MEK/ERK signaling pathway and receptor tyrosine kinases [23], prolongs the survival of patients with HCC.